The three largest US drug distributors and a major generic-drug manufacturer have agreed to pay more than $250m (€225m) to settle the first federal trial over the companies’ role in fuelling the US opioid epidemic.

Some 675 jobs are to be created following massive investment in the biopharmaceutical and software sectors in Cork, Dublin, and Galway.